Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Research & Development (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Research & Development for 2 consecutive years, with $21.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 54.81% to $21.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.7 million through Dec 2025, up 25.45% year-over-year, with the annual reading at $73.7 million for FY2025, 25.45% up from the prior year.
  • Research & Development for Q4 2025 was $21.7 million at Pyxis Oncology, up from $17.8 million in the prior quarter.
  • The five-year high for Research & Development was $21.7 million in Q4 2025, with the low at $13.0 million in Q1 2024.